Rapt Therapeutics, Inc.

Rapt Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. It utilizes deep proprietary expertise in immunology to create molecules that modulate critical immune responses underlying these conditions. A key asset is ozureprubart, a long-acting anti-IgE monoclonal antibody in phase IIb clinical development for prophylactic protection against food allergens, offering potential for less frequent dosing every 12 weeks compared to existing therapies. This targets IgE-mediated reactions responsible for most severe food allergies, complementing treatments for at-risk adult and pediatric populations. Rapt Therapeutics, Inc. addresses significant unmet needs in allergy and immunology, including severe reactions leading to emergency care and impacting patient wellbeing. Founded in 2015 and headquartered in South San Francisco, California, the company plays a vital role in advancing immunology-focused biopharmaceutical innovations for inflammatory diseases.